Healthcare Industry News: TYRX
News Release - August 13, 2007
TyRx Pharma, Inc., Announces the Hiring of Mark Citron as Vice President, Clinical and Regulatory AffairsMONMOUTH, N.J., Aug. 13 (HSMN NewsFeed) -- TYRX Pharma, Inc., today announced that it has hired Mark Citron as Vice President, Clinical and Regulatory Affairs. Mr. Citron replaces Mason Diamond, DDS, who has elected to pursue other opportunities.
"Dr. Diamond provided significant contributions to TYRX and we wish him well in his next venture," remarked William Edelman, President and CEO for TYRX. Mr. Edelman continued, "We welcome Mark Citron to TYRX as the Vice President for Clinical and Regulatory Affairs. His tremendous depth and experience will support our strategy in the combinations product, dug and medical device sector as TYRX moves from the development stage to a full commercial footing."
Mark Citron has worked within the regulated medical products industry both in the US and internationally for over 20 years. Most recently Mr. Citron served as a corporate officer for BioMimetic Therapeutics, Inc., (BMTI) an emerging leader in the development and commercialization of drug-device combination products for the repair of orthopedic injuries with global responsibilities in preclinical, clinical, and product development and approval, involving drugs, devices, biologics and tissue based products and their combination. Mr. Citron previously served with the US Food and Drug Administration for over 4 years where he was a scientific (microbiology) reviewer and field inspector. Subsequently, he was with Johnson and Johnson for 4 years, Bristol-Myers Squibb for 5 years and Genzyme Tissue Repair for 3 years. Therapeutic areas covered in his career included orthopedics, OB-GYN, wound care, hemostasis, dermatology and cardiovascular. In addition, he has served on numerous standards committees and industry organizations to include the ASTM, AdvaMed, Biotechnology Industry Organization (BIO), Orthopedic Surgical Manufacturers Association (OSMA), American Association of Tissue Banks (AATB) and coauthored several articles and book chapters. He is Certified in Regulatory Affairs (RAC) and was a certified lead assessor (ISO- 9001). He holds a BS from the U of Mass- Amherst and an MS in Microbiology and Health Sciences from Wagner College.
This notice follows TYRX's March 19th announcement that the paper entitled, "Prevention of Experimental Pulse Generator Pocket Infection by an Encapsulating Antibacterial-Coated Mesh" was accepted for presentation during the Heart Rhythm 2007 Society meeting, (May 9-12, 2007, Denver, CO). TYRX Pharma sponsored the study at Newark Beth Israel Medical Center (Newark, NJ).
On October 16th, 2006, TYRX Pharma, Inc., filed a Premarket Application for PIVIT(TM) CRM, an innovative mesh pouch coated with TYRX's proprietary bioresorbable polymer. These polymers contain the antimicrobial agents, rifampin and minocycline, and are designed to enclose a pacemaker or ICD pulse generator when implanted in the body. PIVIT(TM) CRM acts to provide protection from microbial colonization of the pulse generator during surgical implantation. According to a recent study presented during the Heart Rhythm Society 2006 Scientific Sessions (Boston) the University of Pittsburgh Medical Center noted that the 2003 national incident of infection for pacemakers was estimated to be 5.82% and for ICDs 3.71%. Recent market research indicates that more than 500,000 pulse generators are implanted each year.
About TYRX Pharma, Inc.
TYRX Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes combination medical products utilizing novel biomaterials technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination products. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space. For more information, please visit www.TYRXpharma.com.
Source: TyRx Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.